Helicobacter pylori Virulence Factors and Clarithromycin Resistance-Associated Mutations in Mexican Patients.
Judit Alarcón-MillánJosé Bonilla-DelgadoGloria Fernández-TilapaNayeli Goreti Nieto-VelázquezMónica Sierra-MartínezVíctor Manuel Alvarado-CastroEnoc Mariano Cortés-MalagónPublished in: Pathogens (Basel, Switzerland) (2023)
Persistent infection with Helicobacter pylori (H. pylori) is an important factor in gastric diseases. The vacA and cagA virulence factors of H. pylori contribute to the development of these diseases. Triple therapy containing clarithromycin has been used to eradicate this infection. Unfortunately, resistance to this antibiotic is the primary cause of treatment failure. This study aimed to determine the prevalence of clarithromycin resistance-associated mutations and to assess the relationship between virulence factors and Mexican patients infected with H. pylori . The cagA and vacA genotypes were determined by multiplex PCR. Furthermore, a qPCR was used to identify mutations of the 23S rRNA gene. This study reported a prevalence of 84.3% of H. pylori among patients with gastric diseases, and the vacA s1m1/cagA+ genotype was the most frequent (44.8%) in antrum and corpus. Analysis of the 23S rRNA gene revealed a 19.8% prevalence of clarithromycin resistance-associated mutations. The most prevalent mutations were A2143G (56%) and A2142C (25%). A significant association ( p < 0.05 ) between the A2142G and the vacA s1m1/cagA+ genotype was detected. In conclusion, we report a high prevalence (>15%) of clarithromycin resistance-associated mutations, and we found an association between the genotypes of virulence factors and a mutation in the 23S rRNA gene.
Keyphrases
- helicobacter pylori
- helicobacter pylori infection
- escherichia coli
- pseudomonas aeruginosa
- end stage renal disease
- staphylococcus aureus
- risk factors
- ejection fraction
- newly diagnosed
- biofilm formation
- genome wide
- chronic kidney disease
- prognostic factors
- copy number
- peritoneal dialysis
- gene expression
- stem cells
- high throughput
- cystic fibrosis